Partner
Dr. Antje Brambrink is qualified and admitted as an attorney at law in Germany. She advises and represents clients in complex patent disputes on all IP-related matters, often at the interface of antitrust and regulatory laws. Her expertise covers various fields of technology with a focus on pharmaceuticals, biotechnology, med-tech, as well as renewable energies and high-tech. Our clients appreciate Antje's deep understanding of the life sciences sector based on her dual qualification as a licensed dentist.
As a patent litigator, Antje represents clients in infringement, preliminary injunction and inspection proceedings before German district and appeal courts as well as in nullity and compulsory license proceedings at the German Federal Patent Court and the Federal Supreme Court.
In addition to her work as a litigator, Antje advises clients strategically on all issues relating to intellectual property rights (patents, utility models, supplementary protection certificates), such as contracts for the licensing and transfer of rights also in connection with international transactions or the newly established Unified Patent Court (UPC). She has extensive experience in the European coordination of multinational patent disputes.
Prior to joining Finnegan, Antje practiced patent litigation for several years in the patent litigation teams of two international law firms seated in Germany. Antje's medical and scientific background is of great benefit in advising clients from the life sciences sector. Renowned pharmaceutical, biotechnology and medical devices companies regularly seek her advice. She also advises in the field of renewable energies and in the enforcement of standard-essential patents.
Antje frequently comments on recent case law in German IP journals. Intellectual Asset Management's Strategy 300 named Antje as a Global Leader for 2023.
Coordinated a European patent dispute on pharmaceuticals*
Represented a company in compulsory license proceedings*
Federal Patent Court of Germany
German Civil Patent Courts
EPO
Represented a pharmaceutical company before German Civil Patent Courts*
German Civil Patent Courts
Represented a pharmaceutical originator before German Civil Patent Courts*
German Civil Patent Courts
Represented a renewable energy company in infringement and nullity proceedings*
German Civil Patent Courts
Federal Patent Court of Germany
Federal Court of Justice
Event
Unified European Patent Law Lecture Series Unified European Patent Law Lecture Series
April 22, 2024
Osnabrück
Event
2024 FCBA Global Series Spring Session 2024 FCBA Global Series Spring Session
April 15, 2024
Washington
European IP Blog
UPC’s Court of Appeal Paves the Way for More Transparency UPC’s Court of Appeal Paves the Way for More Transparency
15 April 2024
Event
Pharma & Biotech Patent Litigation Europe 2024 Pharma & Biotech Patent Litigation Europe 2024
January 22-24, 2024
Amsterdam
Articles
9 Takeaways from the UPC's First 6 Months in Session 9 Takeaways from the UPC's First 6 Months in Session
December 21, 2023
Law360Media Mention
The Legal 500 Deutschland 2024: Finnegan’s Munich Office Ranked The Legal 500 Deutschland 2024: Finnegan’s Munich Office Ranked
April 2, 2024
The Legal 500Commentary
Patent Plausibility Faces Uncertain Future at the EPO Patent Plausibility Faces Uncertain Future at the EPO
February 21, 2024
Law360Commentary
Top 5 Cases to Watch at the Unified Patent Court Top 5 Cases to Watch at the Unified Patent Court
February 20, 2024
Law360Press Release
Finnegan Announces 2024 Partner Class Finnegan Announces 2024 Partner Class
January 2, 2024
Award/Ranking
10 Finnegan Attorneys Named to the 2023 IAM Strategy 300 List 10 Finnegan Attorneys Named to the 2023 IAM Strategy 300 List
October 5, 2023
Intellectual Asset ManagementPress Release
Managing Intellectual Property IP Stars: Finnegan Scores Top Patent Rankings Across the Board Managing Intellectual Property IP Stars: Finnegan Scores Top Patent Rankings Across the Board
July 13, 2023
Managing Intellectual PropertyDue to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.